0001628280-22-000404.txt : 20220106 0001628280-22-000404.hdr.sgml : 20220106 20220106071300 ACCESSION NUMBER: 0001628280-22-000404 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220106 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 2seventy bio, Inc. CENTRAL INDEX KEY: 0001860782 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 863658454 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40791 FILM NUMBER: 22513620 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02210 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02210 8-K 1 tsvt-20220106.htm 8-K tsvt-20220106
0001860782False00018607822022-01-062022-01-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 6, 2022
2seventy bio, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________________
Delaware
001-40791
86-3658454
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
60 Binney Street,
02142
Cambridge, MA
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (339) 499-9300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per shareTSVTThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01. Other Events.
On January 6, 2022, 2seventy bio, Inc. issued a press release announcing that it has entered into an option and license agreement with Novo Nordisk for the joint research and development of an in vivo gene editing treatment for hemophilia A and that it has entered into an agreement with Genevant Sciences for access to Genevant’s industry-leading LNP technology platform for use in the collaboration with Novo Nordisk. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
__________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
2seventy bio, Inc.
Dated: January 6, 2022By:/s/ Nick Leschly
Name: Nick Leschly
Title: Chief Executive Officer

 EX-99.1 2 exhibit991-8xk162022.htm EX-99.1 Document
Exhibit 99.1
header1a.jpg
2seventy bio Announces Expanded Collaboration Agreement with Novo Nordisk to Continue Development of in vivo Gene Editing Approach
Collaboration further validates 2seventy bio’s megaTAL™ gene editing platform with potential applicability across company’s oncology pipeline
2seventy bio eligible to receive $40M in near-term payments, in addition to future milestone payments and sales royalties
2seventy bio and Genevant Biosciences announce collaboration for lipid nanoparticle delivery of megaTAL mRNA
CAMBRIDGE, Mass.— (BUSINESS WIRE)—January 6, 2022—2seventy bio, Inc. (NASDAQ: TSVT) announced today that it has entered into an option and license agreement with Novo Nordisk for the joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for hemophilia A patients with the goal of offering a sustained therapeutic effect.
“This collaboration aims to develop the first direct in vivo application of our megaTAL technology. We are excited to explore this technology with Novo Nordisk, with the goal of developing a new potential therapeutic approach for patients with hemophilia A. Moreover, we view this work as further validation and a natural extension of our technology platform. Based on what we continue to learn, this technology may play a potential role in expanding our gene editing platform toward future in vivo and ex vivo applications that can enhance our oncology pipeline,” said Philip Gregory, D. Phil., chief scientific officer, 2seventy bio. “We are also excited to announce a partnership between 2seventy bio and Genevant Sciences for the use of Genevant’s lipid nanoparticle (LNP) platform in our collaboration with Novo Nordisk.”
The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in 2019, focused on identifying a development gene therapy candidate for people with hemophilia A. The collaboration utilizes 2seventy bio’s megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components. Hemophilia A is a genetic bleeding disorder resulting from defective Factor VIII.
“We are excited to continue our partnership with 2seventy bio to jointly develop a next-generation in vivo genome editing treatment, with the ultimate ambition of offering people with hemophilia A a lifetime free of factor replacement therapy,” said Karin Conde-Knape, senior vice president, Global Drug Discovery, Novo Nordisk. “This partnership reflects Novo Nordisk’s commitment to utilizing novel technology platforms to advance truly disease-modifying therapies for people with serious chronic diseases.”
Under the terms of the agreement, Novo Nordisk will obtain the option to exclusively license 2seventy bio’s in vivo mRNA platform and gene editing technology for use in the treatment of patients with hemophilia A. 2seventy bio will receive an upfront payment of $5 million and is eligible for near-term milestone and option exercise payments of up to $35 million, in addition to development, regulatory, and commercial milestones, as well as a royalty on net sales. Novo Nordisk will be responsible for funding all research and development activities.

header1a.jpg
Related to this collaboration, 2seventy bio has also entered into an agreement with Genevant Sciences for access to Genevant’s industry-leading LNP technology platform for use in 2seventy bio’s collaboration with Novo Nordisk for the treatment of patients with hemophilia A. 2seventy bio plans to use the Genevant LNPs platform for efficient delivery of megaTAL mRNA to hepatocyte cells within the liver.
“We are very pleased that 2seventy bio has entrusted Genevant and our LNP platform with delivery for its important gene editing program in hemophilia A,” said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation. “Our scientists have been at the forefront of the LNP field for more than 20 years, and we are excited for our innovative technology to be used for this important application with great unmet need.”
Under the terms of the agreement between 2seventy bio and Genevant, 2seventy bio obtained rights to license Genevant’s LNP technology for use with megaTAL mRNA products in the treatment of patients with hemophilia A. Genevant is eligible for upfront and near-term option exercise payments totaling $10 million, as well as development and commercialization milestones, and royalties in the mid-single digits on future product sales.
About megaTALs
MegaTALs are single-chain enzymes that combine the natural DNA recognition and cleavage processes of Homing Endonucleases (HEs) with the modular DNA binding properties of transcription activator-like (TAL) effectors. This protein fusion architecture allows the generation of highly specific and active nucleases in a compact format compatible with all current viral and non-viral cell delivery methods.
About Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
About Genevant Sciences 
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development. The Company’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit www.genevant.com. 
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour — to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering new therapies and leveraging platform technologies that truly disrupt the cancer treatment landscape.

header1a.jpg
With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: Twitter and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
2seventy bio Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements”. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, including statements regarding: plans for the expansion of our oncology pipeline and the development, regulatory approval, manufacture or sale of our current or future product candidates; expectations regarding use of our megaTAL technology for the treatment of patients with hemophilia A and other genetic conditions; expectations regarding use of Genevant’s LNP technology for the treatment of patients with hemophilia A and other genetic conditions; and expectations regarding the benefits we may receive from our agreements with Novo Nordisk and Genevant. Such forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual results to differ materially from those express or implied by such statements, including: the risk that our megaTAL technology is not effective in addressing hemophilia A and other genetic diseases; the risk that Genevant’s LNP technology will not be able to provide safe and efficient delivery of megaTAL mRNA to hepatocyte cells within the liver; the risk that we will not realize anticipated benefits from our agreements with Novo Nordisk and Genevant; and other internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. We caution investors not to place considerable reliance on forward-looking statements contained in this press release. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Quarterly Report filed by 2seventy bio with the Securities and Exchange Commission on December 1, 2021, as well as discussions of potential risks and uncertainties in 2seventy bio’s subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, 2seventy bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

header1a.jpg
Investors: 
Elizabeth Pingpank, 860-463-0469
elizabeth.pingpank@2seventybio.com
Media:
Victoria Wagner (von Rinteln), 703-599-2868 
victoria.wagner@2seventybio.com
Morgan Adams, 774-313-9852
morgan.adams@2seventybio.com

 EX-101.SCH 3 tsvt-20220106.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tsvt-20220106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 tsvt-20220106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 header1a.jpg begin 644 header1a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information Document
Jan. 06, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 06, 2022
Entity Registrant Name 2seventy bio, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40791
Entity Tax Identification Number 86-3658454
Entity Address, Address Line One 60 Binney Street,
Entity Address, City or Town Cambridge,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 339
Local Phone Number 499-9300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TSVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001860782
Amendment Flag false

XML 8 tsvt-20220106_htm.xml IDEA: XBRL DOCUMENT 0001860782 2022-01-06 2022-01-06 0001860782 false 8-K 2022-01-06 2seventy bio, Inc. DE 001-40791 86-3658454 60 Binney Street, 02142 Cambridge, MA 339 499-9300 false false false false Common Stock, $0.0001 par value per share TSVT NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.2seventybio.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports tsvt-20220106.htm exhibit991-8xk162022.htm tsvt-20220106.xsd tsvt-20220106_lab.xml tsvt-20220106_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tsvt-20220106.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tsvt-20220106.htm" ] }, "labelLink": { "local": [ "tsvt-20220106_lab.xml" ] }, "presentationLink": { "local": [ "tsvt-20220106_pre.xml" ] }, "schema": { "local": [ "tsvt-20220106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tsvt", "nsuri": "http://www.2seventybio.com/20220106", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tsvt-20220106.htm", "contextRef": "idd0f8deeed094d2f8d7e0b6280280401_D20220106-20220106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.2seventybio.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tsvt-20220106.htm", "contextRef": "idd0f8deeed094d2f8d7e0b6280280401_D20220106-20220106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.2seventybio.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001628280-22-000404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-000404-xbrl.zip M4$L#!!0 ( )TY)E3V1!AI7A0 %%9 8 97AH:6)I=#DY,2TX>&LQ M-C(P,C(N:'1M[5QK<]M&LOU^?\6LG.NUJTB*I"3KY;A*EI1$N[;7*RMQ[:=; M V!(3@1@L!B %//K]W3/X,6'8GO7CKS7^>"()#CHZ>D^??H!/O_3Q=_.;_[Q M]E+,BB06;W]^^>KJ7.ST=W??[YWO[E[<7(B?;EZ_$ON#X4CV\>$[OX%\EHQ?_ M\_Q/_;ZX,&&9J+008:YDH2)16IU.Q?M(V5O1[_NKSDVVS/5T5HCQ<#P6[TU^ MJ^?2?5[H(E8OJG6>[[K7SW?Y)L\#$RU?/(_T7.CH^QV]-WYV,-P_D,?!L]'^ M\/!81N-A=# :[QT?A@?A\?#_]HX@Y2ZN=U^RQ3)6W^\D.NW/% EP'GRYQN=*"O>J(6X-HE,_]RS4'+?JEQ/W(56_Z9P1]R<7RZS72@"W%\/!@]WZ7K6[MZ\5PG4R'CXOL=4I+*1W+P:S;=$38/U]YR5GNB+M6+7U=M9\1@KMM08 MXE15OJ+'0(:WT]R4:=3W*IWP?Z?W*/@\I=DR*'5LUAT!+$6@C MSM(4(H0XMLN[3*81S/?*S7NABYEX8^8&_^21AG$7!A>G MA4Y+)2ZP:&PROM),A$[%7./2'U6JQ&4$3X-+G&59;F0X$VOGN5V-F8PB?+2-WMOS':'I4:9IO<:(+7!YV=+^_4?==W4[*O)BI7,SQ[0C0847[;!X_ M.AJ/#D^M2-14WIR]JI3VI;9V[T8@W/[1^/1+R_21ZA93,C_ES2^+93$Q>>(L M.3,%-*UE+&2683D9Z%A#\S+,C;4B- G\85D?@DE)_.E29#I3=*?_MS;J[$=_O#UP0 J9)Y'UM)1":7! RV1V_3WMG\\95)692Y$I!7 MV<+@K*HK!;!(6(FW16Z6 'JM[#>-D\9),82J>G9^]?GE]=?'C M94^\EM8.V&6_/#3=#T1/7O[\[NK-Y;MWXOW5]>53+^-?9%I*G,&S'K-"_V[[ MN'OB*@T'XLF;LW<79W]__.C@Z%3I^IQ&0SA"(IS@;B9J9MZZB"4L>1%65&AREL&<+O[:2, MA;K3EA=+2D!E?XD#:\ZMBP>!*A9*I7S Q<+X0 =X'8B?P?_$Q> A@^)6?C8>#T_9?KKG+S5.%H?DU?X+. M?LD9&DK;MN&.8W1]H0LVKR&( 2? K11T3-Y%4BU,?BL05%:RE2J@X-82)$X2 M".'VMJ6"UGXJ[CT0+]G=<=&" M:"Z(I/(0DY@%AI;TT;B>050,Y;>\P-: RL M07'B2EJ@>VYF_(59R#RJZ.8W"_\$"\=1/W"]J;N'J+<&&:SC:"%(DTIGDJ@Z M6>Q:9MEC\!Z=(O\!:W]+_IF)'W,U-?FR)RX&_-:@)\*95A/!_+_0$W@ZPADB M+_RW'7@'PL<"#SXRMJ:-0'7: -]"'YU M01WQ-V0?3UZ]>?NT<4]8/&FB&ZC6('#@]?+U1>.;V6I6=A_];K,\)E9(6G5* MB+>9T5GDL#C+ZL2"N%2!!MI5)]99'*H>#T?'/9Q:6'HDUA%;T-)%DC;/8C1U MP61)AAMQG@F)B/M<4B )K%_G*';& 5'8K\FI8@X$#^U M22/1WOJJ(%:*(PQ4"#TJ)M?$M/'6)#<)=$8\D8H?/\BPP&U^N;JZ^GIIXSI/ MJ8,T^6D;)_C\.R"!JSEQQ-E4')/HR5W1)W5ZBWC@H>1!AF"HSR0;\L86-22; M3,A#91+HFHU66QFE'6LXKRE M;6:YFL3P,-NYO$80>'&B71H(ZW-H0QM.<8]X$PWE#$A&"MU^M8]P;>71"9H2]YWE)@4^^._:KS=";4S]U?V9OPDH8U[)_8$9<6F! MA%#IO76 KP,!OKB8]PI%]9*&-5' ZU:2ND43XF/^?)HR"0[VOARP@^1\RE55 M'ZRUS!#LL(8OTM-:WQU0\3ZNDD%X;=T1(!&:%D!3XJ?KO+VH.Y6'\)VF[(\E MRXSLZ+N]>N6UKD&+H?0@W[2$1I@;T]*$!;0JH*:^I^U1 KM0V(ZDN.Y:"DOB M/@CPKL\PV&#A@:) #X)@ZQU-2I=KRCC>7AF5Q 4T]2RV_;#C^K9/Q0POB8K<+RK6"O@=;,[)LDNI5NI M^:]D&)O3-LD59+K16M:FTZBT1;[LQS@9LGBD;)M":1MJ-@+][V1U=?KX:1@% M,5+> (E R]0;A;RV*V63'6SK?M%",X6;FW )%A4",9P('D?Y6U\]K^>=@\QP M)8Y3K363PHLR"J!K,MQN9GFDM/] M]HFNU#L4%/^J+!;+< 8R^78VN!CT&A[I,)XK'X@>82OG0*&LJHWLEP#447SL"= ^BVVMKU9%;QE)Q#E&F"<)4B&?WO99J_ M7WE:04!'0Z%'[NW;=@-J#=16,*R"+E9Q!P=@JE%)^<;'$JC: E>ID"=/G\(G MCXY&A\='GR.E?%#LELZX(8Q;*6)AB,,#3KX;#1N*V.)W'2;6883Z-^=2'6*( M*^H1D^JX$QWU:8J3!B5PAD1,TZI[X$W#L\8-HXEM97[NX8>SP)1%9;H?,2'S MX4.=_Y&C?>T%9(!TBNV',\H>5?K;DJ9&76G<)(%V%<>ZJW0!;T0.8J:IKGM. M(6+7''R5SH((C&(8^V4+.J^)6D0]+ M&5%)MTI!D\%AKOW(!#%YRB[ZL;Y5X@DV\=1WA4UN?8,>"Q1*DX%P]XM2 D2 MD*T%>8)9N#IFJ_R%^VPJ7TI70VRDI\3'=>A#'@](G)((@(*J&$&92%CF.9G[ M7)/*V)%,VG>OB,0T(1H!9&:B!V*W'1YX]OC1_N'INX\8#OW"1MRMHU,>65'C MJ2MM(8>)BUE(-N['!ZG,7O)4+4YR=#S>X[.A7.>?IE44QPO;">J2(YQ BMA\82!^J.B=3IVW<6R9:^B- MBHDF]75*'.^FT/EY+="-+$; 0H#2L?2-N4(VV-&4-58FE:HL078:(!W M'2X3HE(U_9XFNJ3NJ "?Q1\]7XH,9>38#!; YA7W]]UZQ'1*+FSTKZ7&RX1;O6T!.+F48DH_($ M9^NV*".MHFIBOTG+)>+6;[@ 4!WF5$ZH*'O=P;95M=H-%GI)6YEAH&;:R^2& MXSC.IHA-/$XUQVV1)NH^"?B$Z)@%UTJ?(@:F,J"I=8G#IS9UGDM603/IV)X( MH=)V&)=L2G,$31'[[HN;:IMVB*7X,MWOD^F'8,L9WI/UB@(-:6RD1U"Q.]IFFYF"VI.@0V50V]X<^^N+EZ?3D0Y]2$ MS 4R#I@CM6 ES2Y4U38>]G-4T WBN1)5(N]T4B:4/M ,AT];J'D 2YJ5B:0\ MEFA9X0O";#I< !N-3L7X<.B28%"G7,SH1G[XG&XTU7ZDM^IY*B*7<^5=##+6 MHXP\J^*;I34HZB0I4].O!YLX ZFG2!IF7 ^@1+X=S(C*J[16N\L3Y M$#DJS2LME%^<:@B(&'XB 4APFYI%K*(J'>38Q?,U[0(#+FI2L!UNGG5565CY<\&9U#453L:41"X :HQ=K. MO%36W=92Y@SKX;/#X93:M[]EB8M2"N\^0_;"(4Y4HM%EMS#!:J[90S%7OZ!7 M2I +DW'_BHB*8@(3R>6G-Z<^MU_=DUL[*D(,I0J@-+A*).4![X8*>RN="'!2 MXR8/P,PD/ZWEMN;38_<"9^C^J'+EA[O+SO8X\0%^18J**C ]MXOUQ]7^X%RW M(_0Y?(U^Y0'>\8XR)$:4:S65.2,:C)*>#.B_,H9K4O4U?V@M_2-GE7P1FBIN M8"K,^6E>$RAE*V29^'W&?I^VWJ<'G($X S W;S>0FIJB_3Z7KFUA#=?2MENW0TOK#GEU.NYQ1]?AKZ8$?$;>1GT[?ITDB(=_Q*>?48>$G_&O9 MJVGXS8\"?>S00ZO,VTPNIVXBZH/$^)!.Z']6GJK*W^@ SM9),SG_M ;=?HOMP-G))UT7BG3FQN/H=IS]W7].55O MG5+WAK]G)3P41_>&DTO_U'\UD&_E1*W,X/];4S:;Y%NH1@08*CU3@%MB5SKC M@:G:J#[>BAJC=>K2-$Y%#UW0W-"=_]L-17>, WN4X(41B&&O/L=&>AU+>)'L#A/Y@2^9.5:]KSZZ*V=@S]6JV.R(_^83=3$N)K*.@ M*18J(X0N0F/U.37EI_#^^CGFFO%6G1T M]3+)98?2UL&$SYW!81T/>FW3J,=TO#WTJM-V!*=@%CB1TTK4S^NNS)E[X5 MHB&/L[(6+N^\C9_3V#WKSUU7_?\"6)X$V."(?]=@U)W.J)7.7*+U/.=FS6^= M*P2B6_7/DA^0'#RW["BJ?NR+?#8!%?9%X7J.B9^/JAZ< M;Z[F8!BJK.!+R8P65(7/L0&=NP.H?H8&9A[+Q*]CJ:F53_[_/8[N952?5'Z?P7'H(^T2GG(+P MESY%P*/QX-GQF#17X)"*J+JQ%W_ 2MTMHO7/CH\&Q\/M'P\'H_JS75[;K8\= M6&0-W^_L[33GSK\'=#+.[L2H^VM ])M!JYMP\G^VY'OS+^!=50&Q54BH;;JU MQQ6[&1VX,[UWWT/:]5>IJ[44V/U:(,WV!8 S\1:B8@.W/7'T;-C??[;7'^X_ M.]ZDMZ]YOZK:[R#S^WW\Z-G^Z4KY[)NU;/:LUW5Y[IN&-MO7+YK8(U+(]W*: M@B(\F8-K7%-2%%.7^W"XUS\X/NZ/CYX=;0>FKUD!/ 1 ='-V="TR,#(R,#$P M-BYH=&WM7>MWVKJR_W[^"EWVO?NT:U5@V?*+MCDK.Y I$W7WBVV7J/1:/2;T4C^\J_),$1G/$F#./I:(F6I MA/ZU]>5_,/[/7X?[J!:[XR&/,K23<)9Q#YT'60^=>#P=(#^)A^@D3@;!&<,X M+[,3CZ9)T.UE2)9D^49B4C5T7W815N:/*AJ'X#E$X553=)+KI<%TC M+C6YH4BBV5X&O8,>1NG74B_+1M5*Y?S\O'RNE..D6R&F:58F(D^IR%2=A$$T M6)U5I"ZR!I,,I]R]EAF>R]WXK!)$D),+#E:RA$6I'R=#E@&'*[)$5"P96"&7 M]5RK8N(D8=XBY%2N5'2EV>7Y[VI3EK D8R)?=#,-EG52EB12^8^U?^3V^)#A M($HS%KE\42Z-7UBF\Q_7IVD>RPM,A>#5G4 M_5KB$3X^*L$ <^9M?1GRC"%1'O/_CH.SKZ6=.,I ;'%K.H)B;O'TM93Q25;) MQ[NR]8]__.-+%F0AW\K2LPP+@96(I'VI%"^_5(JJG=B;;GWQ@C.49M.0?RUY M03H*V;0:Q1$' H))563D2?$S\#P>Y3\AW8:YDP1NT?XD.^3^UQ)DD'S#XYQ[ MDDD]&7[K7'(TV9#@/RJ13FU!R@5-)12QH6B:!]5Z!/1-=Z ["0L;D<J%KY,75J\=F^?'C65JRQUZ^?G>Z9_>;P1V"W&K19LX?M?GUVVCJ8V2U7 MM>#_]O!8L?N[?;L6ALV:=;ZOV&%[-@K;_>-IL]:=G0X;$TL^EJS9L=)LU97F MR;?0GK4G[=F!>MKJSJQ=@]B!.72'NU%S:(=V?S"Q6G5BU0ZAC@/5GH6]TY,# MV=K[$=I[;7@?]MMR?;:O'/;:PTG8'-9)L_57[W1H]T]K='4R #O6TUE6: MM8$*>:5FS:5VZUA=E(&VQJ?RL=:&=];>[K MVP.K=:#8M3JU9N% Y&^VH)W6 M ;5G76*W0M_:D2;[K7IF'4F39NN8V-L=0_85@_D$FU1Q01VI#F8&=;'D*D3S M79-K!$98@DEA:))NR%\JUX;U.4=Y&Y2N)Q3O;LBZ)53,9:AVDE7]8,(][+-0 M3(CW8;]OV(]N#/MYAWFRK*JZBCU',3#5504S&"!,="Y+,.2:[^FEK5W!X%LC M7KD^QQ/N\X2#)DN7J":AMJIIKDI!)E"^>%0S4$A?2VDP'(5"G^7O>HD0F6M: MJ#Q)/:BB*YJ%D^!)Y[]@" %%NAN'<5+]0\K_?/:AAZ JAD$XK?ZS%0Q!3FU^C@[C(8O^^2D%E 0)@G\ M(F,:S'B5&$!@_G@^IQCJ$U6_>@ZS1M([5%]Y_BP MT6K4C]"V74/U_^S\>]O>JZ.=IF4UCHX:37ME%X8LZ<+P.7&6Q<.J LT]?Z>D MM3IUPM)>$'6S./J$:N6=,F!NE9H;U9'U1F>W>6BA9UQ,%T9, 09?<\F<[,NG MT_:)J]FUW8$]&TS;LQ]#JS68P/.P/1LHIZU>O]VW^U;_L-=L#^ M5YOB\EI"M#-.$F&H'O)1G&3H^SA)QPR>LWCC23_BKK#3$%%0G""B?O ^HMA' M68^O.9FU%YG,:W=FG 19 #76)VX/$!%'VVXF.D1,A6Z4>EI/SPH(("Q[V/U9?09=]S*%,O ,YU \&#-W@(;?9$,>RQ*9YREF > M_<[*;U;O>#K5*5=GD7QI M79:EPL+,P([-O$7+\^1RGE3)O"5I1IDHJY.E,EE=]*YJ%2!(?O)J%;DL*\KS M5*NN56TE9W#!9!A'(11?2Z XKTM#51Y-$%F&:VX.9C&.+X]VI!=9/D#[Q0E MI7QOXB@#L+(3CZ,LF>[$WG4D([97A+LGXZ,D/A/UO%$(LQLX>\?::?]'V&SM M]NS6MZ!]TE#LO1\]^^3;T)I9LEVS0ZM6%^Y.I2U;\S(_H"TU.FV-AO;)L6J= MU(DU_-9K]UWI%'ZWH45KUI: YG.K)=R=7K]-C//]UG8V=WNJ=JL^[1"B [11 M9'[)PE2WR>;4((Y,N0L2;&A8T52#JO1. MO?TV(,J]ID@NQ!]RT"!<9#@,4A&R@\0R@8I9]NOULW%XA.K#41A/>9(/[77E@NRX_'&9G"_HG->F%/;7 MG:(O"7:4UN+=8[,N)X[0-:C["63UVP"F;<]+>)K._]D' LC[NG/?NC.[82VH M'<,U5$W57:SYBHFIKU+,?,JQQGQ5U67#T!6P%C0)_15$$9^BHRSA//OTTPCJ MKEF5Q.?%;WG3%-F&"?_W&.SE\#08%<;TN_3?*_U745>#=#19\W2F$$RX*6-* M '4Y&C.P[^BNQE19UU0)[ :9T-4[ P_2]6LMS;D%_%L*] [\;":M^/S=\W.O M-$O7=7ECTC$,12*JZ6*3RB+@FJD@S8J'5=EP/1A(717A7CMLZ"2!U^6WE#AZ M1N?/KRRUN8723+XG\5F0QSF_B^Z]HEN_*KJSCDX-GW"J8*XQ%U/3U[##= ES M3P.!4RC1#5;:LK9_PEVY#)S_&A;R7 S%3MWW!"0P&+$0U2?<'6?!&4=-'RPH MGC[$7GR S?,V6 08"0F0M,1^K.2;;AL2=;->C,KE?NR??Q@RT3^GJ,5#/NK% MT<([D.\[AV,Q1&@[X2SO?15]>$:=*!9OT=2;!:-/%23TVOM$5-$YN*)&U.",>:2L*.,[0]&H6@ M@D&_;7S$R6Z< &.1G8><)&C^.%_:/J' %V$F49=[Z$B ++3/TD44WNK D^LJ M/(\2^;5C46YW^-FECRX/T.UQ=R""6A$;C9)XE 3"B^_$$^3P,#X7XRD2Q3 C M _^-_" 42U60HD"G]?$QI8M5[8!'K;)_4;3H]X8NW9/:#K_+1E09_:DM4_'31;#17HIO:P<=[< M.U;MFMUK_P :K_GKK/..2[GL4LW$7)S1H8;B8E,C*M8]4P7[P5,]7RYM_?F' MJ5/Z>6W/QXL)\5/AA5R; ''8YA1:6R.E_6Q7I^Y?B).'7R M@>AH9_<0R0JH25E]W&;Q;?ZMU#'W9'W7,:MUS%$,A@F,7-2U !@*4M\5S$\J MF!N;N]:L0XCDJKIJ8M5C"J:4,&3_U=%,REP*'A7.)N:Q=" M&2;R%05S[5#;A7JA@+/RG.\:9G,US/>$"P0CKD[(CP,+HS)I^K[P>[UKFI_2 M-.2&IB$=Q9 4HKL&!DS#,!7G[$S)HUB2?8_I5)%-F?PNF@8$#[M7).]>3$.H MA^4/SL?U]$Z1]UWSO!G-TTC3,4_>]<_3Z1_EAOY1.JH/>-]D%&L^53$U/0DS M*A/L2!HWF&_ZKDG?]<\J_:-P3#^XZ^F?>=[';Z0JK^:3OF(M%DYBGG#O&CLN M[F;(U?'<:0PLJ*)?V?W[."_EG<2&+$W70%SOW)MS+V&"V/P\U-%TZ,3AASM"^9Z8?\E"8?ZR[+7G5YSD MLLD7J!<@X'DO@#>7./'^ Y:_D^R:KVUCS['\E,A.KE_>LM$\VYY8_3H8RX.I M-7.I73N>M?M@](+A"X:T9/?;Y/2D+3=K!S>-YIE5JT\M,);!4)[9LZYDM^P M:);@?S"D#V2[_R,\[;>IO6M,KQO-!^<=3>:<>+Z/54G7,>!*AAV-F-A7=5=R M%56G)BEM"5<&S(>C+'8'G]#_YI8&02.6H#,6CCD:B2MB>P^Y2N)]HKS@1)FO M'\72\3Y+UI@E5\^('JT)\)97Z5>?'XN%9.'Q*FZYN^F@%17\!5Q,9*Z\%?>"(HIKF)5T(<__R":_CF/C5EDAF9 ZD?B\CX1=%UX M@V4'RTOJ6G:_ZT6EPC-\6>Y*M>7U+[5]I8&IKV#R@O 7V9)ZF;L\%UW=RWNZ M4W3T5]R->JI#(@<=6>..H3H$$T67,*6$8]/S=,Q5F<@Z415=G.3)-Y:TU1M+ MFRK[#?\.-?,)E,M2G17<"K3O@4;B(7?%-Z.B.-]*&:<\SP42/ _G%Y\I"O+M ME>++#$+N\K;"J6@\_]:4F'@1] U2$GX6I% .]!R+7!&NPUQ7W!TH,HLO"GDL M\=(BD-];M8^C?& 7^SA7%5CYEYS>D]8%CXL;H]_G]NJY?=SA3)-T;A"L$D\5 MX7$*-G3'Q41U9=VG#*#)&O&W=V\(OK7=0$UZ^JM@3;U,M<=5>]\^T'JU;O11 MB.7$W;XZ9'VC<74S*U'RU>_5C.)"A503'C)Q@OS6%VPN"W MB]SWT9N'?GE'N?ST3B^YY&^78R?A;("9#^BSRL)S-DU+E>?Z/L_+K^/+3T\V M,CY$1EDBY?DM>?E'"M)UP??EP4A8\:%@57D]2-*,T(T[^>'O6Q>J@X&4CF'1 M9[#^BZL/0%0Y \3!H@@@@BL@0M9C8$?-L4E4Q'H$$8 #Z%,\RN$!8 @4!BZ/ M1,ENPHMPF1R(V/%9#'\EH)0'.5 1"*(?0P705LI9XO;RXAY0%L:CO&"'\:C7A &#&WGM=Q%ZPW"Q$'%,P%SCMR@ M^!:9J!&@D6 #E%BD7]P, $,Z!I@VA04I]P2B??L[RKC;BV!$NU,$:TXF4$)> MCT!MT '1V7Q= -BZF64"'9Q&/ MIV7-A?6PA#^^_VS\*>CSN#M':]4\D%OD IK84DS#BZGW^=4)1,7W<.?TF";! MQF1 - '\R[ULF(>S ZX\G.-*0)NWK8%/R,M!X@W# 10*NVG!/73#B#X',KIY M0\QRF5_GVI?U,*ZI+L.XM^#LQMQO=M38L[=;QX=W?&MV]%CH"P-) M5)1/MGF&'IA+8V%+Y=6Q<=:+$^B&'FC>;NOO*;):4+(>VXC/&7O4F7O_%SN'^-:T^ M003H6^IQ):T@.W ':)^G;B^$$^Z(3OE%2?VIO!/+QN&6_\/4$L#!!0 ( )TY)E3,8Q^'A ( M -@' 1 ='-V="TR,#(R,#$P-BYX'F>>J=@/_+&#B%*"IHV"&RZJ:RA( M4VIJPWXUI*0%A5QWO033UQ[@R*R(6(+Z1BJ0-Y'= MMB283J?>UM3HH'T'%SPCRJ[%JRVQ>&Q$'(1X&+A;F3O>N\+V'5$F%6$9G!-; M_\(=[U_D<)CO>3ETO/-SL,XD9.Z2K[TO%KP&H2C(XQNR#E8" MBIEC+@EW6_NS)*FK,^D@SP+T1V#,GJ9 N3A4TG'5KM9T5[M^C([Q_[A7?J[B10(R'_SN96 M/FU@2VXA;Q S4F9->3[OD-:KM%;9#:@]8*]_P?O?1U=N%?NG8S[X#5!+ P04 M " "=.2948*Q%]:T* #_8 %0 '1S=G0M,C R,C Q,#9?;&%B+GAM M;,V<76_;.!:&[_LKM-F;76!82^*'J*+-H)MI!\5FVJ)-T<$N%@:_E CC2(&L M-,F_7TJV$RF2;)*R5=^TCDT?ON>U'AZ*E/3ZU_OKA?=#%T!/?CU]\>+UWP#X\U]?SKW? BBD*$HCB#R%?GE\A6CU)=4"$ E)@ QHE\A' _4@@%0<@9QG7019K] M]:KZA[.E\G1RV;+^\\W)55G>O)K-[N[N7M[S8O$R+RYGH>_#V:;UR;KY?:?] M':Q;!W$8,MJK_ IAFHW@)!"&#P\GXI3TY?>-[*CB)?J"\J\:K_OWWY,-AE/*M: MS#)U6?VRGU61YO)KR8KRG'&UT.KK:.7#C7ISLDRO;Q9J\]Y5H9+^L(NB:$6M M5,:5RH!4*O\^U-ELA/P]Z2V[6O<@KD[WX[XT;O/TX][D7NCQ01U><*.;T9)7 M!]2[3$YU[#YV-5KZX17OZ[#(2[:8X+!XZJ8A>5&]<:Y?K;NI FT93.M^UD-W M0ZJZ+U4FU6JT;(7V4OGF1+^:2Y7./Q?J++_6=4^HJOA=5-\I/B6)*N88Z?"" M,R"%+D&(A@3$'#+ T)0%/$81FQ>/A[93+HYLYZT5>\=-VJ*AV=9>Q:+6_8^@M::S4E6,D_U4J!:$CU5EJ]6NSKV5-R MSKXN)G)K<8Q&Y:(E:%%-%O+BN0^Y,/3A"<&E3J$V8:G$R\O\QTP'T&:$0?4" M5"]J\G:$G75^U;?%1C$KQ [;URUF(M>A;TK0^@6J.:1-:F5NW-U8K,=:3(<>Q-H$MC?P!ZZ M=UF9E@]OI=0_Z5*?%93J4_&YR'^D6N*<0YP(?6(( LQTQ0U#KBMN[ /*"8L0 MY(($B2F#VSHZ-B176KVUV%^\6JZVU-L(-J=TJ[^[H=V7:P=FV-TP*ZQ-W'"B M?&O@R: W2:\Y!ABU=QT2WMU?%"Q;IM72R>J\:^X3'!&*8H!00@"2E !*$ =1 MD"#$&6/2AW;#0;>3(QT*WMU[3TJ]E53;0:#'4=,!8)Q/T\!O99$#]L,>C$"^ M)^C$N ^GU45]2UM7S"_8_0>IIQ%IDJZ623_>7G-]4@AI A$45$^_B9Y^8Q7H M\^P( YD(/Z(^BQFU9'V@IR,%7JOUVG*]E5Y;ZH<,-D5_#[9-P[^]8PZ#P XW M1HP$0Y$G'@YV)-@=$W9]P7Y@^*K$;:$C!R&_2,N%FOM,$*Q/[H$*A2[^*H$@ MQOJL@%,8Q81ASD5H.A8\#WYL^->BO#SQ@O ?_)_>1JXY]1WW=H,^QI,#LVUK MAQ720WD[4=P)-AFX0VDT61ULXUJWWZ<+M:XD2L4QPDD$*)2)QI,Q0!/F Y^H M0-#0YR&V+-5/P8\-SW6MJ00ZUN.&<:8EV,V.::JNB1,.=;:;\HC2V@@V<37M MIM$MH#UM[*'\KN$N558MBM]FZT*\G(=&Y%NFU59HCVF_C;DY'FW-@6"U]L0)V:^Y.U/9'G S=K0DU^=W> MT![B9[M:'Y;+6U4T=TJ9'X4X40HD0:A/BB'7/".F0!SY'/N,1Y(95]I=G1T; MVIWMU97B_6Q'=ZW>S?P^#3PP_J.\&[-#/6C*/O:IN\%_UF[U8)I;]JR'O^.\ M8GZMBLLTN_R]R._**]W7#YA(FE), 8Q]'R *D^JJ%3T[Q[&*41S[<6Q\ MUBNQWEJM]=)YK[7&J^=C#9MH =W2*Y+>4+"0 1$ H&(QAXF"# 9$9 0&$5, M3_T)4J;8MR(?&^AK<=Y*G3G8;;MVH^QLPJ%7R,SRMX*U-U&7P;ZQ4!!&(,88L)\B ,91J;P]?9P M;! ^WBNR4NEIF5ZETQS'?B-W8SG:G@/C:>V,%:A;LW<"MC_B9.!N3:@)\/:& M#IM.^2(5::G'A#]TH")EBSGQF6(8 M;R_T5^>484ICQ8'T,02(Z8++B1^ @*&(5;<5)HS:EMDJ\+&A^5A#*G'V);7V MRKR2VCHP50'=FKQ3U6QF.JI8UH$FKY%-^7VEL?6Y/6IGU;6=A6)GN51SHA23 M7)=!OP(,A4B F!,(!"8J".*0!DR:HM8,?&RHG=67$6MQ7J7.G+666;M9<[7@ MP*P99F\%6U^J3K"U DT&6Y_\)FR]G[NNX'[(1%[(&^])UNL6KV/M0NL77B76^Y2Y MWE[5,M9TU!AIUS1CA;U3[O=5]3DQ_J:J5M2?9@FY%3Z>KL_U-QD=]EOE(GT%66AVGT U#+2?0;C9-/'TV M^<_5/&65Q5@VY= :T6WM\'(0O$Y7Y9L\9_TIEY1%%QA1"4% M$4E"@*(X ''"(0B0/B_3A833Q/B&UN%NCKUN& MJ57NI:/7B?'5HQWVYQ20WM0&:TA_:U?\SU2FQY'%ATRJ^W^KA[G$!/LJID!4 M$T2$$P@X3JKG8#*N3^ DBZGEB"A+LU##=T?1_'N7ESIWT_5JW^)Q%(PA4$,.0&(^!CP M.(H!@EC0D"H<"F..^SHX-HPW&KV-2,LEU%X3=S,\UIH#(VSIBM/#*?I2'_6 MBE; R1]2T9=.WX,J>ML-P=MT_%R_.GVQ>2==/3'_],7_ 5!+ P04 " "= M.294Y+>-]?$& !6,P %0 '1S=G0M,C R,C Q,#9?<')E+GAM;-6;6U/< M.!;'W_D4O3VO*UHWRQ(5F&*99(M:9D(E3&5J7[IT.0)7NFU*-K=OOT>&GH1 M9ERXMW!>H+'5/M+__*QSL7GS\^UZ-;N&U%9-O3]GNW0^@]HWH:K/]^>_G[TC M>O[SP<[.FW\0\L>_/IS,?FG\U1KJ;G:4P'809C=5=S'[%*#]/(NI6<\^->ES M=6T).>B_=-1/.%D5_T555?][+/YQM88:+J]O^S_WY M1===[BT6-S3C_X"UI94==O9VF<#;;77]@=/&F^[7O._G=?LNR/R7V0SC.1#A'$B MV.YM&^8'.[/9O1RI6<$'B+/\^_Y#&+C9-M'=[6 M7=7='=>Q2>M^PIMSN)C^XMW=)>S/VVI]N8+-L8L$<7_>M=<=R5ZGC*H\I9\& M77?Q9>*7"=H\/)\_P0,/E\]S_'\L FX[J /<2[>9PZKQCP:MLN.:M/GFRCI8 M]4>7 :KE48/WTJ%KNV1]MT2':&:](XIEN"4MB0O"$F-M"6"L<)P_UBPOJL55 M]7YNP>^>-]<+O##ZF[/\(0O:^_>G)^;NE7O9O#>"G.'8952%"\QJ$K621'H# MQ(;"$\L8P]LP<*K"J&E_;>WQK+_V^&'RLR8%2+@O;^N[A^91WNUM"/W(;' M3R%5#=XAX1?+*4!*F&*C 1%D:V(KK'YD=Q "?/@,O MU_*58;C?(#_ >965J+O?[!J67FH7(@CBJ08BN7#$\4*2H#$82U=XY\4H%IZS M.@@%,5T41BLY"1*.,05,ETWJA?^(^L-1ZH";"T96%M=)X4P1LBRP*( M 5=B,J8""&Z$$^46P/C+20SB1$Z=D^WI/ ELWE4K^.UJ[2 M@P,O*"TP$AI* M)(."."DE*1UN?085D\YO@9$O%@%B*] MC<;IDD07L'9#;HDQ4I HF!,A *5T7$[QE^8'<:&FSL4VM)T$)(@R". ^61!HD"Y$J8^@6 'G&]" XRJG#,5;3*8%QA!_? MI[/FIEXJA!@UX425'K,FP3TQD46B'>Z(6%^!EW%[6'PQ/ @*_8- \4(]IX1$ MGQ>]3Z>IN:YJG^LJ::PSG,2"UQ\8WU07"8'P2. M,VF09&D)E3Q76P:(IEYA%HWEMZ ANE)NCX]'MH:<)C:'([7A-3"DP MO&GM98%I$"_&W?K/FAT&PH1[F./%?&4:/C:KRE==59__B@E.JNQJJ273I;,% M@2AR],I:*-S9.$>!@F%>EN.:V4]M#N-@PCW*D3*^,@2G"3+!@(EM_WPN/]I- M[R/.8\D"Z$AMP&F#R''-$$^Y99DG18GKM2C#*,8Y16R?[0+%8CE81AS#8"@Q\.ER7/KP=S,8!LJ$&Y=;E?BU PKX M*PR*=XR[LZI;P1(*K(:]!:("E40&51*-51"*XH+S3&DMQO6FOK4X#(<)MRI' M2?C*[C]+-K\0]_%N[9K5TFJC2L@QT#"LBF+NN0?/B&2N$)%%7(\9Y?M'YH8Y M?L+MR)>+-Y&;_NVMO[#U.?2/\I7DPMH02"D5;EHA2H(+<82#9[R0@)_'-1^? MLSJ,@0EW'4=+.8ENX]LUI'-$^=^IN>DN,+A=VOINZ;3B5#E+G,'-3.J( @WAJ>1@9$VY$;D7226!QA'HENSK&S/?V/W"W ME((5+F+T*Q0H(H66Q!7:D3(:235P+\IQ^<.S9H'VY'@Q7YF&0RR#0BZ% MWJWL^5*J6)0L*&)4D>'5!3$0*?%4"'"&>2/'A8U'YH9Y?\(]R9>+MS6OOUD\ M$>\$#QSL/)S(/_(_8ASL_ ]02P$"% ,4 " "=.294]D08:5X4 !160 M& @ $ 97AH:6)I=#DY,2TX>&LQ-C(P,C(N:'1M4$L! M A0#% @ G3DF5.TWLA&D% UX\ !$ ( !E!0 '1S M=G0M,C R,C Q,#8N:'1M4$L! A0#% @ G3DF5,QC'X>$ @ V < !$ M ( !9RD '1S=G0M,C R,C Q,#8N>'-D4$L! A0#% @ MG3DF5&"L1?6M"@ _V !4 ( !&BP '1S=G0M,C R,C Q M,#9?;&%B+GAM;%!+ 0(4 Q0 ( )TY)E3DMXWU\08 %8S 5 M " ?HV !T